Authors: Ma KL, Liu ZH, Cao CF, Liu MK, Liao J doi: https://doi.org/10.1101/2020.03.19.20034124 Abstract Background Notwithstanding the clinical hallmarks of COVID-19 patients were reported, several critical issues still remain mysterious, i.e., prognostic factors for COVID-19 including extrinsic factors as viral load of SARS-CoV-2 and intrinsic factors as individual’s health conditions; myocarditis [...]

Authors: Iglesias J, Vassallo AV, Patel V, Sullivan JB, Cavanaugh J, Elbaga Y PMID: 32194058 DOI: 10.1016/j.chest.2020.02.049 Abstract Background: Sepsis is a major public health burden resulting in 25% to 30% in-hospital mortality and accounting for over 20 billion dollars of US hospital costs. Research question: Does hydrocortisone, ascorbic acid, thiamine (HAT) therapy improve clinical [...]

Authors: Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ PMID: 32192578 PMCID: PMC7270045 DOI: 10.1016/S0140-6736(20)30628-0 Abstract As of March 12, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%,1 compared with a mortality rate of less than 1% from influenza. There [...]

Authors: Zhou Y, Fu B, Zheng X, Wang D, Zhao C PMID: 34676125 PMCID: PMC7108005 DOI: 10.1093/nsr/nwaa041 Abstract Pathogenic human coronavirus infections, such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV), cause high morbidity and mortality [1,2]. Recently, a severe pneumonia-associated respiratory syndrome caused by a new coronavirus (SARS-CoV-2) [...]

Authors: Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE PMID: 32190813 PMCID: PMC7069762 DOI: 10.1055/s-0040-1705137 Abstract An individualized approach to identify acutely ill medical patients at increased risk of venous thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of extended thromboprophylaxis (ET) is needed. The International Medical [...]

Authors: Wu D, Yang XO PMID: 32205092 PMCID: PMC7156211 DOI: 10.1016/j.jmii.2020.03.005 Abstract COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type [...]

Authors: Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z PMID: 32171076 PMCID: PMC7270627 DOI: 10.1016/S0140-6736(20)30566-3 Abstract Background: Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients [...]

Authors: Yang SN, Atkinson SC, Wang C, Lee A PMID: 32135219 DOI: 10.1016/j.antiviral.2020.104760 Abstract Infection by RNA viruses such as human immunodeficiency virus (HIV)-1, influenza, and dengue virus (DENV) represent a major burden for human health worldwide. Although RNA viruses replicate in the infected host cell cytoplasm, the nucleus is central to key stages of [...]

Authors: Li K, Wu J, Wu F, Guo D, Cen L, Fang Z et al. PMID: 32118615 PMCID: PMC7147273 DOI: 10.1097/RLI.0000000000000672 Abstract Objective: The aim of this study was to investigate the clinical and computed tomography (CT) features associated with severe and critical coronavirus disease 2019 (COVID-19) pneumonia. Materials and methods: Eighty-three patients with COVID-19 [...]

Authors: Kanne JP, Little BP, Chung JH, Elicker BM PMID: 32105562 PMCID: PMC7233379 DOI: 10.1148/radiol.2020200527 Abstract Infections by COVID-19 continue to increase in China and worldwide. The betacoronavirus was first reported in December 2019 in Wuhan, China. As of February 24, 2020, the World Health Organization (WHO) reports 78,811 laboratory-confirmed cases, including more than 2200 [...]